Cargando…

The Duration of Intestinal Immunity After an Inactivated Poliovirus Vaccine Booster Dose in Children Immunized With Oral Vaccine: A Randomized Controlled Trial

BACKGROUND: In 2014, 2 studies showed that inactivated poliovirus vaccine (IPV) boosts intestinal immunity in children previously immunized with oral poliovirus vaccine (OPV). As a result, IPV was introduced in mass campaigns to help achieve polio eradication. METHODS: We conducted an open-label, ra...

Descripción completa

Detalles Bibliográficos
Autores principales: John, Jacob, Giri, Sidhartha, Karthikeyan, Arun S, Lata, Dipti, Jeyapaul, Shalini, Rajan, Anand K, Kumar, Nirmal, Dhanapal, Pavithra, Venkatesan, Jayalakshmi, Mani, Mohanraj, Hanusha, Janardhanan, Raman, Uma, Moses, Prabhakar D, Abraham, Asha, Bahl, Sunil, Bandyopadhyay, Ananda S, Ahmad, Mohammad, Grassly, Nicholas C, Kang, Gagandeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388294/
https://www.ncbi.nlm.nih.gov/pubmed/28003352
http://dx.doi.org/10.1093/infdis/jiw595
Descripción
Sumario:BACKGROUND: In 2014, 2 studies showed that inactivated poliovirus vaccine (IPV) boosts intestinal immunity in children previously immunized with oral poliovirus vaccine (OPV). As a result, IPV was introduced in mass campaigns to help achieve polio eradication. METHODS: We conducted an open-label, randomized, controlled trial to assess the duration of the boost in intestinal immunity following a dose of IPV given to OPV-immunized children. Nine hundred healthy children in Vellore, India, aged 1–4 years were randomized (1:1:1) to receive IPV at 5 months (arm A), at enrollment (arm B), or no vaccine (arm C). The primary outcome was poliovirus shedding in stool 7 days after bivalent OPV challenge at 11 months. RESULTS: For children in arms A, B, and C, 284 (94.7%), 297 (99.0%), and 296 (98.7%), respectively, were eligible for primary per-protocol analysis. Poliovirus shedding 7 days after challenge was less prevalent in arms A and B compared with C (24.6%, 25.6%, and 36.4%, respectively; risk ratio 0.68 [95% confidence interval: 0.53–0.87] for A versus C, and 0.70 [0.55–0.90] for B versus C). CONCLUSIONS: Protection against poliovirus remained elevated 6 and 11 months after an IPV boost, although at a lower level than reported at 1 month. CLINICAL TRIALS REGISTRATION: CTRI/2014/09/004979.